Riskpilot← Back to searchSign inGet full accessMATRIX PHARMACEUTICALS ApS
APSActiveCVR 29625867Amerika Plads 32B, 5. 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20061 employees
Revenue 2024
DKK 981K
-18% vs 2023
EBITDA margin
51.9%
-57% vs 2023
Equity ratio
22.3%
Financial strength
Net profit 2024
DKK 440K
-19% vs 2023
| Revenue | DKK 981K | -18% |
| EBITDA | DKK 509K | -57% |
| Net profit | DKK 440K | -19% |
| Total assets | DKK 269K | +196% |
| Equity | DKK 60K | +236% |
| Employees | 1 | — |
Legal name
MATRIX PHARMACEUTICALS ApS
CVR number
29625867
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
26. juni 2006
Share capital
DKK 500.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at importere/eksportere, sælge, markedsføre og distribuere lægemidler.
Address
Amerika Plads 32B, 5. 2
Phone
+4544840600
Email
karsten@matrix-pharmaceuticals.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.461 | 8.648 | 929 | 450 | -40 | 267 | 0 | 35 | 849 | 843 | 1.166 | 1.193 | 981 |
| Staff expenses | -25 | -25 | -0 | -0 | -226 | -521 | -489 | -223 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 239 | 1.126 | 929 | 450 | -265 | -254 | -545 | -187 | 849 | 843 | 1.166 | 1.193 | 509 |
| Depreciation & amort. | -0 | -0 | -3 | -3 | 3 | -3 | 3 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 239 | 1.126 | 926 | 447 | -268 | -257 | -547 | -188 | 849 | 843 | 1.166 | 1.193 | 509 |
| Net financials | -160 | -165 | -172 | -102 | -70 | -112 | -90 | -122 | -118 | -67 | -586 | -649 | -69 |
| Profit before tax | 79 | 961 | 754 | 345 | -338 | -369 | -638 | -310 | 731 | 776 | 580 | 544 | 440 |
| Tax | -0 | -0 | -0 | 135 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 79 | 961 | 754 | 211 | -338 | -369 | -638 | -310 | 731 | 776 | 580 | 544 | 440 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.263 | 3.148 | 4.516 | 2.859 | 2.986 | 2.191 | 1.942 | 167 | 96 | 120 | 96 | 91 | 269 |
| Equity | -1.128 | -167 | 587 | 797 | 459 | -1.238 | -1.875 | -2.185 | -1.455 | -678 | -80 | -44 | 60 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2.391 | 3.315 | 3.930 | 2.062 | 2.527 | 3.428 | 3.817 | 2.352 | 1.551 | 798 | 177 | 135 | 209 |
| Total debt | 2.391 | 3.315 | 3.930 | 2.062 | 2.527 | 3.428 | 3.817 | 2.352 | 1.551 | 798 | 177 | 135 | 209 |
EBITDA margin
51.9%
This company
15.8%
Market median
+228% vs market
20122024
Equity ratio
22.3%
This company
38.2%
Market median
-42% vs market
20122024
Return on equity
733.7%
This company
18.4%
Market median
+3888% vs market
20122024
Net profit margin
44.9%
This company
8.1%
Market median
+454% vs market
20122024
Asset turnover
3.64×
This company
1.12×
Market median
+225% vs market
20122024
Debt / equity
3.49×
This company
0.62×
Market median
-463% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Audit | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2010 | — | — | |
| Board of Directors | 2013 | — | — | |
| Chairman | 2014 | — | — | |
| Chairman | 2006 | — | — | |
| Board of Directors | 2009 | — | — | |
| Board of Directors | 2006 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
KHS HOLDING ApS | Company | 100.0% | 100.0% | 2020 |
| Individual | 100.0% | 100.0% | 2020 | |
| Individual | 50.0% | 50.0% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
KHS HOLDING ApS
MATRIX PHARMACEUTICALS ApS Board members of MATRIX PHARMACEUTICALS ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| GRANT THORNTON, STATSAUTORISERET REVISIONSAKTIESELSKAB | Audit | 0 companies |
| Peter Lassen | Board of Directors | 0 companies |
| Anders Leif Håkansson | Board of Directors | 0 companies |
| Steen Larsen | Chairman | 0 companies |
| Mariann Florin Skafte | Chairman | 0 companies |
| Christoph Kerstein | Board of Directors | 0 companies |
| Stefan Gliwitzki-Grabner | Board of Directors | 0 companies |